1. Home
  2. BCG vs CELU Comparison

BCG vs CELU Comparison

Compare BCG & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BCG

Binah Capital Group Inc.

HOLD

Current Price

$2.05

Market Cap

39.8M

Sector

N/A

ML Signal

HOLD

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$1.27

Market Cap

34.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCG
CELU
Founded
2016
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.8M
34.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BCG
CELU
Price
$2.05
$1.27
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
10.0K
31.7K
Earning Date
03-30-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.04
N/A
Revenue
$178,203,000.00
$40,578,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$76.00
P/E Ratio
$58.30
N/A
Revenue Growth
10.19
N/A
52 Week Low
$1.36
$1.00
52 Week High
$5.81
$4.35

Technical Indicators

Market Signals
Indicator
BCG
CELU
Relative Strength Index (RSI) 38.55 44.78
Support Level $2.26 $1.20
Resistance Level $2.45 $1.31
Average True Range (ATR) 0.14 0.07
MACD -0.04 0.01
Stochastic Oscillator 0.00 41.75

Price Performance

Historical Comparison
BCG
CELU

About BCG Binah Capital Group Inc.

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: